AFT Pharmaceuticals Limited (NZE:AFT)
New Zealand
· Delayed Price · Currency is NZD 2.780
-0.040 (-1.42%)
Jun 6, 2025, 2:19 PM NZST
AFT Pharmaceuticals Income Statement
Financials in millions NZD. Fiscal year is April - March.
Millions NZD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Revenue | 208.02 | 195.41 | 156.64 | 130.31 | 113.11 | Upgrade
|
| Revenue Growth (YoY) | 6.45% | 24.75% | 20.20% | 15.21% | 7.11% | Upgrade
|
| Cost of Revenue | 116.31 | 107.14 | 83.66 | 68.54 | 64.36 | Upgrade
|
| Gross Profit | 91.71 | 88.27 | 72.98 | 61.78 | 48.74 | Upgrade
|
| Selling, General & Admin | 65.05 | 58.09 | 49.4 | 37.99 | 36.69 | Upgrade
|
| Research & Development | 9.77 | 6.47 | 3.91 | 3.62 | 1.97 | Upgrade
|
| Other Operating Expenses | -0.75 | -0.53 | - | -0.23 | -0.63 | Upgrade
|
| Operating Expenses | 74.07 | 64.04 | 53.31 | 41.39 | 38.03 | Upgrade
|
| Operating Income | 17.65 | 24.24 | 19.67 | 20.39 | 10.71 | Upgrade
|
| Interest Expense | -2.82 | -3.69 | -2.87 | -2.44 | -3.44 | Upgrade
|
| Interest & Investment Income | 0.03 | 0.07 | 0.01 | 0 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.73 | 1.11 | -3.14 | 0.64 | 0.24 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.46 | 0.3 | 2.13 | 0.09 | 0.38 | Upgrade
|
| EBT Excluding Unusual Items | 16.03 | 22.02 | 15.8 | 18.69 | 7.89 | Upgrade
|
| Pretax Income | 16.03 | 22.02 | 15.8 | 18.69 | 7.89 | Upgrade
|
| Income Tax Expense | 4.63 | 6.41 | 5.15 | -1.16 | 0.11 | Upgrade
|
| Earnings From Continuing Operations | 11.4 | 15.61 | 10.65 | 19.85 | 7.78 | Upgrade
|
| Minority Interest in Earnings | 0.56 | - | - | - | - | Upgrade
|
| Net Income | 11.96 | 15.61 | 10.65 | 19.85 | 7.78 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 0.19 | Upgrade
|
| Net Income to Common | 11.96 | 15.61 | 10.65 | 19.85 | 7.59 | Upgrade
|
| Net Income Growth | -23.36% | 46.51% | -46.32% | 155.05% | -38.69% | Upgrade
|
| Shares Outstanding (Basic) | 105 | 105 | 105 | 105 | 103 | Upgrade
|
| Shares Outstanding (Diluted) | 105 | 105 | 105 | 105 | 103 | Upgrade
|
| Shares Change (YoY) | - | 0.02% | 0.16% | 1.34% | 6.15% | Upgrade
|
| EPS (Basic) | 0.11 | 0.15 | 0.10 | 0.19 | 0.07 | Upgrade
|
| EPS (Diluted) | 0.11 | 0.15 | 0.10 | 0.19 | 0.07 | Upgrade
|
| EPS Growth | -26.10% | 46.48% | -46.41% | 168.07% | -39.61% | Upgrade
|
| Free Cash Flow | 12.9 | 28.75 | 11.43 | 13.82 | 0.66 | Upgrade
|
| Free Cash Flow Per Share | 0.12 | 0.27 | 0.11 | 0.13 | 0.01 | Upgrade
|
| Dividend Per Share | 0.018 | 0.016 | 0.011 | - | - | Upgrade
|
| Dividend Growth | 12.50% | 45.45% | - | - | - | Upgrade
|
| Gross Margin | 44.09% | 45.17% | 46.59% | 47.41% | 43.09% | Upgrade
|
| Operating Margin | 8.48% | 12.40% | 12.56% | 15.65% | 9.47% | Upgrade
|
| Profit Margin | 5.75% | 7.99% | 6.80% | 15.23% | 6.71% | Upgrade
|
| Free Cash Flow Margin | 6.20% | 14.71% | 7.30% | 10.61% | 0.58% | Upgrade
|
| EBITDA | 18.02 | 24.63 | 19.88 | 20.67 | 10.97 | Upgrade
|
| EBITDA Margin | 8.66% | 12.61% | 12.69% | 15.86% | 9.70% | Upgrade
|
| D&A For EBITDA | 0.37 | 0.4 | 0.21 | 0.28 | 0.26 | Upgrade
|
| EBIT | 17.65 | 24.24 | 19.67 | 20.39 | 10.71 | Upgrade
|
| EBIT Margin | 8.48% | 12.40% | 12.56% | 15.65% | 9.47% | Upgrade
|
| Effective Tax Rate | 28.90% | 29.11% | 32.56% | - | 1.33% | Upgrade
|
Updated Nov 21, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.